Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1301-1306

  Kapetanovic, Izet M ^a   Muzzio, Miguel ^b   McCormick, David L ^b   Thompson, Thomas N ^c   Johnson, William D ^b   Horn, Thomas L ^b   Mohammed, Altaf ^d   Rao, Chinthalapally V ^d   Kopelovich, Levy ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

^c R and D Services Pharma Consulting   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Chemoprevention; Colon tumor; Liver; P53; Pharmacokinetics; Rat

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; PROTEIN P53; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COLON; COLON TUMOR; DIET SUPPLEMENTATION; DISTRIBUTION VOLUME; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ANIMAL; BIOAVAILABILITY; COMPARATIVE STUDY; DRUG EFFECT; FISCHER 344 RAT; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; COLON; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIVER; MALE; PYRIMIDINES; RATS; RATS, INBRED F344; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862275394     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1811-9     Document Type: Article

References (19)

1. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM (2010) Targeting the p53 pathway of apoptosis. Curr Pharm Des 16:2493-2503
2. Athar M, Elmets CA, Kopelovich L (2011) Pharmacological Activation of p53 in Cancer Cells. Curr Pharm Des 17:631-639
3. Bossi G, Sacchi A (2007) Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 29:272-284 (Pubitemid 46339325)
4. Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53-62
5. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1:68-76 (Pubitemid 33741882)
6. Farnebo M, Bykov VJ, Wiman KG (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396:85-89
7. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510
8. Jiang L, Sheikh MS, Huang Y (2010) Decision making by p53: life versus death. Mol Cell Pharmacol 2:69-77
9. Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L, McCormick DL (2011) Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology 289:141-150
10. Muzzio M, Huang Z, Johnson WD, McCormick DL, Kapetanovic IM (2011) Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS. J Pharm Biomed Anal 56:809-814
11. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L (2009) Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 69:8175-8182
12. Rao CV, Swamy MV, Patlolla JM, Kopelovich L (2008) Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/? mice. Cancer Res 68:7670-7675
13. Sebastian S, Azzariti A, Silvestris N, Porcelli L, Russo A, Paradiso A (2010) p53 as the main traffic controller of the cell signaling network. Front Biosci 15:1172-1190
14. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117:3753-3764 (Pubitemid 350224086)
15. Tanner S, Barberis A (2004) CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed 3:5
16. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799 (Pubitemid 39070849)
17. Wang W, El-Deiry WS (2008) Restoration of p53 to limit tumor growth. Curr Opin Oncol 20:90-96 (Pubitemid 350190987)
18. Wang W, Rastinejad F, El-Deiry WS (2003) Restoring p53- dependent tumor suppression. Cancer Biol Ther 2:S55-S63
19. Wiman KG (2007) Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv Cancer Res 97:321-338 (Pubitemid 46528994)